Skip to main content
Premium Trial:

Request an Annual Quote

In Shift to Drugs after Ocimum Deal, Gene Logic Plans Name Change

NEW YORK (GenomeWeb News) - Gene Logic said today it plans to change its name to Ore Pharmaceuticals in order to better express its drug repositioning identity now that it has agreed to sell its genomics business to Ocimum Biosolutions.
 
The company said two weeks ago it plans to sell its genomics assets to Ocimum for $10 million as it completes its restructuring into the pharmaceuticals field.
 
Gene Logic said the new name has been approved by the board of directors and now awaits shareholder approval. The company also is waiting for the shareholders' nod to proceed with its proposed sale to Ocimum.
 
Gene Logic said it will shift ownership of its name to Ocimum when the deal closes.
 
“We believe that the Gene Logic name is a valuable brand that appropriately should remain with the genomics business of Ocimum Biosolutions," Gene Logic CEO Charles Dimmler said in a statement.
 
The company said it is currently collaborating with eight pharmaceutical companies to reposition some of their compounds. The pharma partners include Abbott, H. Lundbeck, Merck Serono, Organon, Pfizer, Roche, and Solvay.
 
Gene Logic also said its technology program includes the use of its own genomic and toxicogenomic databases, for which it will hold full and exclusive rights to use in its repositioning business.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.